Mechanism of Action
Meso-zeaxanthin is a form of zeaxanthin: same atoms, same bonds, but one of the two ends of the molecule is oriented as a mirror image. Chemists write it (3R,3'S), where dietary zeaxanthin is (3R,3'R). Only an assay able to separate these mirror forms can tell them apart.
In animals, the retina makes it from lutein. Work on chicken embryos and in cell culture attributes this conversion to an enzyme already known for its role in vision. This mechanism would explain its presence in the human macula, although the diet supplies almost none.
After ingestion, trials find it in the blood. Per milligram ingested, its plasma concentration is 2.5 to 3 times lower than that of ordinary zeaxanthin. The measurement comes from a twenty-two-day trial in nineteen volunteers.
In humans, what is measured is the deposit: macular pigment optical density, read without any sampling. It adds up the three pigments without telling them apart, and rises slowly, over several months.
Key Benefits
- Moderate
A denser macular pigment: in adults with healthy eyes, a synthesis of forty-six studies (3,189 participants, mean age 43) measures optical density rising by 0.04 units between 5 and 20 mg per day of lutein and the forms of zeaxanthin, meso-zeaxanthin included, and by 0.11 units above 20 mg, over three to twelve months.
- Emerging
Less disability and faster recovery of vision under glare: in 59 young healthy adults, twelve months of lutein, zeaxanthin and meso-zeaxanthin, at 10, 1 and 1 mg or at 20, 2 and 2 mg per day, improved the glare disability threshold and recovery time after glare versus placebo.
Dosage & Forms
In trials, meso-zeaxanthin is most often given suspended in an oil, within a mixture of macular pigments. Its share of that mixture varies widely from one trial to another, from a few per cent to the majority.
Low-dose trials supplied about 0.5 to 2 mg of meso-zeaxanthin per day, with 6 to 22 mg of lutein. Over three months to one year, macular pigment density rose versus placebo. Many trials used 10 mg, with 10 mg of lutein and 2 mg of zeaxanthin.
The synthesis of forty-six studies counts meso-zeaxanthin in the total pigment dose. Below 5 mg per day in total, it records no clear change in the pigment. Its strata from 5 to 20 mg, then above 20 mg, measure a rising gain, over three to twelve months.
In the Singular Formula
Inclusion rationale
Meso-zeaxanthin is a yellow pigment that the eye holds in reserve. Lutein and zeaxanthin, related pigments, are also present in the formula, and it is that association the trials have covered. In adults with healthy eyes, pooled trials measure a denser deposit of pigment after oral supplementation. A placebo-controlled trial in young healthy adults also records less disability and a faster return of vision after glare. These measurements, made in humans on the association, are the reason it is in the formula.
Selected form
XanMax® 2505 is the carrier raw material, an extract of Tagetes erecta flowers obtained with hexane and ethanol. An isomerisation step under alkaline conditions converts part of the flower's lutein into meso-zeaxanthin, without changing its atoms. The xanthophyll crystals are formulated with dextrin, gum acacia and tocopherols, which slow oxidation of the pigment. According to the manufacturer, meso-zeaxanthin makes up about 3 to 3.5% of the material; only the sum of the two zeaxanthin forms, 5%, is guaranteed.
Composition and Origin
Origin: Plant — Tagetes erecta flower.
Allergens contained: None.
Allergens as traces: None.
Allergens above are declared under European Union regulations. The label of the delivered product carries the declaration applicable to your country of delivery.
Formula dosage
0 to 2.55 mg.
Dose expressed as pure active substance, excluding excipients and carriers of the raw material.
Synergies in the formula
Safety & Precautions
Trials have given meso-zeaxanthin at 0.3 to 17 mg per day, always with lutein and zeaxanthin, with no serious adverse effect reported. A six-month trial at 10.6 mg per day monitored routine blood tests and recorded no adverse finding. In rats, thirteen weeks at up to 200 mg per kilo per day produced no compound-related effect. Tests on bacteria show no mutagenic potential.
No authority has set an acceptable daily intake specific to meso-zeaxanthin, and the European authority has not assessed it on its own. An international committee regards lutein, zeaxanthin and meso-zeaxanthin as biochemically and toxicologically equivalent. It left meso-zeaxanthin out of its group acceptable daily intake, as specifications are not available. In the United States, two food-use notifications were closed without objection.
No trial has administered meso-zeaxanthin during pregnancy or breastfeeding. During these periods, the formula limits lutein to 10 mg per day. The meso-zeaxanthin supplied by the same raw material then falls to approximately 1.3 mg.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Wilson LM et al. | 2021 | Meta-analysis | Advances in Nutrition | View on PubMed |
The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis Forty-six studies, 3,189 adults with healthy eyes, results stratified by total pigment dose, meso-zeaxanthin included. From 5 to 20 mg per day, macular pigment density gains 0.04 units; above 20 mg, 0.11 units. In each of the two pooled analyses behind these figures, six then five placebo-controlled trials, about half supplied meso-zeaxanthin, from 0.53 to 10.6 mg per day. The meta-regression finds no difference in effect between supplements with and without meso-zeaxanthin. | ||||
| Stringham JM et al. | 2016 | Randomised Controlled Trial | Eye and Vision | View on PubMed |
Macular carotenoid supplementation improves disability glare performance and dynamics of photostress recovery Fifty-nine young healthy adults (mean age 21.7), randomised for twelve months between placebo and two daily doses. The first supplies 10 mg of lutein, 1 mg of zeaxanthin and 1 mg of meso-zeaxanthin, the second double that. Versus placebo, the glare disability threshold and recovery time after glare improved at six and twelve months. Macular pigment density also rose, with no difference between the two doses. These results come from a single laboratory and concern secondary outcomes of the registered trial. The placebo group counts ten subjects, and the manufacturer of the preparation funded the study. | ||||
| Hu W et al. | 2024 | Meta-analysis | Advances in Nutrition | View on PubMed |
Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Thirty-eight controlled trials compared in a network, grouped by the pigments they combine. Every group, including the one combining lutein, zeaxanthin and meso-zeaxanthin, raised macular pigment density versus placebo. On recovery after glare, only the lutein plus zeaxanthin group, without meso-zeaxanthin, reached significance. The three-pigment group rests there on a single trial of 48 subjects, with no significant effect. The authors rate the quality of evidence as low. | ||||
| Akuffo KO et al. | 2017 | Randomised Controlled Trial | Investigative Ophthalmology & Visual Science | View on PubMed |
The Impact of Supplemental Antioxidants on Visual Function in Nonadvanced Age-Related Macular Degeneration: A Head-to-Head Randomized Clinical Trial One hundred and twenty-one adults with non-advanced age-related macular involvement, followed for twenty-four months. They were randomised to the AREDS2 formulation, with or without an extra 10 mg of meso-zeaxanthin per day. That formulation already supplies 10 mg of lutein and 2 mg of zeaxanthin. Contrast sensitivity, the primary outcome, improved over time, as did macular pigment density and recovery after glare. These gains were comparable in both arms: adding meso-zeaxanthin made no measurable difference. | ||||
| Stringham JM, Stringham NT | 2016 | Randomised Controlled Trial | Experimental Eye Research | View on PubMed |
Serum and retinal responses to three different doses of macular carotenoids over 12 weeks of supplementation Twenty-eight healthy adults aged 18 to 25, followed for twelve weeks on placebo or on one of three doses of macular pigments. The total doses, 7.44, 13.13 or 27.03 mg per day, keep the same ratio: 83% lutein, 10% zeaxanthin, 7% meso-zeaxanthin. Macular pigment density rose in all three groups versus placebo. It rose from the lowest dose, which supplied about 0.5 mg of meso-zeaxanthin. The groups count only five to eight subjects. | ||||
| Connolly EE et al. | 2011 | Randomised Controlled Trial | Investigative Ophthalmology & Visual Science | View on PubMed |
Supplementation with all three macular carotenoids: response, stability, and safety Forty-four healthy adults, six months, placebo or 10.6 mg of meso-zeaxanthin with 5.9 mg of lutein and 1.2 mg of zeaxanthin per day. Blood lutein and zeaxanthin concentrations and central macular pigment density rose in the supplemented group. Follow-up laboratory tests recorded no adverse clinical finding. | ||||
| Thurnham DI et al. | 2008 | Clinical Trial | British Journal of Nutrition | View on PubMed |
A supplementation study in human subjects with a combination of meso-zeaxanthin, (3R,3'R)-zeaxanthin and (3R,3'R,6'R)-lutein Nineteen volunteers, twenty-two days, a preparation supplying 8 mg of meso-zeaxanthin, 10.8 mg of lutein and 1.2 mg of zeaxanthin daily, with no control group. An assay that separates the mirror forms finds meso-zeaxanthin in plasma. Per milligram ingested, its concentration there is 2.5 to 3 times lower than that of zeaxanthin. The authors read this as probably lower absorption, to be confirmed with pure meso-zeaxanthin. | ||||
| Shyam R et al. | 2017 | Preclinical Study | Proceedings of the National Academy of Sciences of the United States of America | View on PubMed |
RPE65 has an additional function as the lutein to meso-zeaxanthin isomerase in the vertebrate eye Work in chicken embryos and in cell culture. It identifies the enzyme that converts lutein into meso-zeaxanthin in the vertebrate eye, an enzyme already known for its role in the visual cycle. The authors describe meso-zeaxanthin as an eye-specific carotenoid with no common dietary source. | ||||
| Thurnham DI, Howard AN | 2013 | Preclinical Study | Food and Chemical Toxicology | View on PubMed |
Studies on meso-zeaxanthin for potential toxicity and mutagenicity Rats given meso-zeaxanthin orally every day for thirteen weeks at 2, 20 or 200 mg per kilo, against a control group. No compound-related clinical, biochemical or pathological sign appeared, giving a no-observed-adverse-effect level above 200 mg per kilo. The bacterial mutation test is negative. | ||||